SCRIP
CITELINE COMMERCIAL

18 Jul 2023 | **News**

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's episode of Five Must-Know Things: Leqembi's US treatment infrastructure; Novartis backs out of BeiGene deal; Transgene's new CEO's plans; Japanese firms' R&D success; and a look at deal-making in the first half.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 14 July 2023, including: Leqembi's US treatment infrastructure; *Novartis AG* backs out of *BeiGene, Ltd.* deal; *Transgene S.A.*'s new CEO's plans; Japanese firms' R&D success; and a look at deal-making in the first half.

This and all our other podcasts are available on the Pharma Intelligence channel on *Apple Podcasts*, *Google Podcasts*, *SoundCloud*, *TuneIn* and *Spotify Podcasts*, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "*Leqembi Treatment Infrastructure: If Medicare Pays For It, They Will Come*" - Scrip, 7 Jul, 2023.)

(Also see "*Novartis Says No To TIGIT, Backs Out Of BeiGene Deal*" - Scrip, 11 Jul, 2023.)

(Also see "*Ex-Novartis Oncology Leader Riva Takes On Challenge Of Transgene Turnaround*" - Scrip, 6 Jul, 2023.)

(Also see "*What's Behind Japan Firms' Higher Approval Rates In Challenging Oncology, CNS Areas?*" - Scrip, 11 Jul, 2023.)

SCRIP
CITELINE COMMERCIAL

(Also see "*Despite Pfizer/Seagen's Splash, Deals Are Staying Small*" - Scrip, 12 Jul, 2023.)

Click here to explore this interactive content online